Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob
Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger.
The medical device manufacturer in January agreed to acquire Axonics for about $3.7 billion in cash, resulting in Axonics becoming a wholly-owned subsidiary of Boston Scientific.
The additional request for information extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both sides have substantially complied with the request, Boston Scientific said in a securities filing.
The merger is now expected to be completed in the second half of 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 04, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters